Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trialGiampaolo Bianchini, Luca Malorni, Roberta Caputo, et al.
Anticancer Research|May 27, 2025
Phase II Study of the Effectiveness of the Germinated Wheat-derived Rigenase Plus Polyhexanide in the Prophylaxis for Hypofractionated Radiation-induced Acute Skin Toxicity in Breast CancerVincenzo Iorio, Pietro Delia, Angela Pia Solazzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trialSandro Pignata, Giovanni Scambia, Gabriella Ferrandina, et al.
International Journal of Medical Sciences|April 16, 2021
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS TrialEriseld Krasniqi, Laura Pizzuti, Maria Rosaria Valerio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia MeridionaleGiuseppe Colucci, Vittorio Gebbia, Giancarlo Paoletti, et al.
Oncotarget|January 8, 2019
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Oncotarget|October 24, 2018
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Breast Care (Basel, Switzerland)|April 2, 2020
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA StudiesMarina Elena Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 11, 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER StudyGiulia Bon, Laura Pizzuti, Valentina Laquintana, et al.
Scientific Reports|July 3, 2021
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trialLaura Pizzuti, Maddalena Barba, Marco Mazzotta, et al.
Pageof 10